Clinical evidence
HELP
14 evidence topics · 3 sources
3.1.6.2Location and study date
3.1.6.4Eligibility criteria
Subcutaneous lanadelumab regimens; placebo comparator
3.1.6.6.1Rationale for using monthly HAE attack rate as the primary endpoint
Primary clinical endpoint
3.1.6.7Statistical analysis description
3.1.6.7.1Number of participants (Planned and analyzed)
Randomized treatment groups
3.1.6.7.2Description of analysis sets
Primary analysis population and model
3.1.6.8.1Participant disposition
3.1.6.8.2Baseline characteristics
3.1.6.8.3Efficacy results
Mean monthly attack rate over 26 weeks
3.1.6.8.4Health-related quality of life and patient-reported outcomes
Participants achieving the AE-QoL minimal clinically important difference
Summary
The trial randomized 125 participants to three lanadelumab regimens (28, 29, and 27 participants) or placebo (41 participants), and 113 (90.4%) completed the study. The primary analysis used the “Intent-to-Treat” population and a “Poisson regression model”. Because three active regimens shared the randomization, each lanadelumab group contained 27 to 29 participants, which limits precision for comparisons between regimens and for uncommon adverse events; injection-site reactions were reported in 45% to 57% of lanadelumab groups and in 34% of the placebo group. The placebo-controlled period does not describe outcomes over longer treatment. Lanadelumab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.